AtriCure, Inc. (NASDAQ:ATRC) Given Consensus Rating of "Buy" by Analysts

AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) has been given a consensus recommendation of "Buy" by the eight ratings firms that are covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have covered the stock in the last year is $43.38.

A number of research firms have weighed in on ATRC. JPMorgan Chase & Co. reissued an "overweight" rating and set a $40.00 target price on shares of AtriCure in a research report on Tuesday, December 17th. UBS Group boosted their target price on AtriCure from $35.00 to $40.00 and gave the company a "buy" rating in a research report on Wednesday, October 30th. Oppenheimer raised their price objective on AtriCure from $32.00 to $36.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. Canaccord Genuity Group boosted their price target on shares of AtriCure from $53.00 to $61.00 and gave the company a "buy" rating in a research note on Monday, December 9th. Finally, Needham & Company LLC raised their price objective on shares of AtriCure from $40.00 to $51.00 and gave the company a "buy" rating in a research note on Wednesday, January 22nd.

AtriCure Trading Down 0.9 %

AtriCure stock traded down $0.37 during trading hours on Monday, hitting $40.96. The stock had a trading volume of 434,968 shares, compared to its average volume of 597,582. The business's 50 day simple moving average is $35.00 and its 200-day simple moving average is $30.54. AtriCure has a one year low of $18.94 and a one year high of $43.11. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of -49.35 and a beta of 1.46. The company has a quick ratio of 2.59, a current ratio of 3.62 and a debt-to-equity ratio of 0.13.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new stake in AtriCure in the 4th quarter valued at about $3,716,000. M&T Bank Corp bought a new stake in AtriCure during the fourth quarter worth $208,000. Charles Schwab Investment Management Inc. grew its stake in AtriCure by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 399,428 shares of the medical device company's stock valued at $12,207,000 after purchasing an additional 4,844 shares during the period. Versor Investments LP purchased a new stake in shares of AtriCure during the 4th quarter valued at $217,000. Finally, Bank of New York Mellon Corp raised its stake in shares of AtriCure by 2.7% during the 4th quarter. Bank of New York Mellon Corp now owns 258,272 shares of the medical device company's stock worth $7,893,000 after purchasing an additional 6,809 shares during the period. 99.11% of the stock is owned by institutional investors.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.